Beyond Air Q4/FY2025 revenue $3.7M (+220% YoY); guides FY2026 $12-16M; filed PMA for LungFit PH II

Beyond Air, Inc.

Revenue $3.7M for FY2025, up 220% YoY; net loss $46.6M ($0.69 per share).
Expects Q1 FY2026 revenue at least $1.7M, full FY2026 revenue $12-16M.
Submitted PMA supplement to FDA for next-gen LungFit PH II (smaller, transport-ready).
Appointed Robert Goodman to Board; international distribution covers 2B+ lives.
Cash $6.9M as of Mar 31, 2025; $2M additional debt financing post-quarter.

item 2.02 item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Robert Goodman

Director

XAIR · Beyond Air, Inc.

Effective: 2025-06-16
Filed: June 18, 2025, 7:59 PM ET

On June 16, 2025, the Board of Directors (the “Board”) of the Company appointed Robert Goodman as a member of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert Goodman was appointed as Director at Beyond Air, Inc..

Action: appointed
Role: Director

Exact text from the filing

On June 16, 2025, the Board of Directors (the “Board”) of the Company appointed Robert Goodman as a member of the Board.

View on SEC.gov

Beyond Air, Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-015650

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.